75%Confidence
0Views
FDASource
2026-04-08Date
Summary
Amerisource Health Services faces a Class II recall for Meclizine tablets due to failed specifications, indicating potential quality control lapses in manufacturing. This could affect distributor relationships and prompt increased FDA oversight of the involved facilities.
Actionable: Assess the recall's impact on Amerisource's distribution network and any potential liability issues.
AI Confidence: 75%
Data Points
firmAmerisource Health Services LLC
classificationClass II
statusOngoing
distributionU.S. Nationwide
productMeclizine Hydrochloride Tablets, USP 12.5 mg, (a) 50 Tablets [5 x 10] (NDC 60687-775-65) (b) 12.5 mg Individual Dose ( NDC 60687-775-11), Rx Only, Dis
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now